News Breaks |
|
|
| January 25, 2013 |
| 08:35 EDT |  | AGN | Allergan price target range raised to $116-$117 at Leerink
Leerink raised its price target range for Allergan shares to $116-$117 from $103-$104 to reflect its positive view of recent acquisitions and the long-term prospects for the company's designed ankyrin repeat protein. The firm keeps an Outperform rating on the stock. |
|
|
News For AGN From The Last 14 Days Check below for free stories on AGN the last two weeks. |
|
|
| June 18, 2013 |
| 09:04 EDT |  | AGN | Wells Faro to host a conference
2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link |
|
| 08:36 EDT | | AGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. |
|
| 07:28 EDT | | AGN | Wells Faro to host a conference
 Subscribe for More Information |
|
| June 11, 2013 |
| 13:09 EDT | | AGN | Allergan has a conference call hosted by BMO Capital
Subscribe for More Information |
|
|
|
|
|
